The global PD1-resistant head and neck cancer market is expected to reach a valuation of US$ 1.54 Billion in 2023 and is projected to reach US$ 5 Billion by 2033, with a CAGR of 12.5%. The growing geriatric population and rising number of initiatives by government and non-governmental organizations such as Support for People with Oral and PD1 Resistant Head and Neck Cancer(SPOHNC) are creating a highly conducive environment for the growth of the global PD1-resistant head and neck cancer market.
The robust presence of the product pipeline and their expected launch will fuel the market growth. Some of the products in the pipeline are Tipifarnib (Farnesyltransferase Inhibitor), tiragolumab (anti-TIGIT), Tecentriq (atezolizumab), Rozlytrek (entrectinib), and Afatinib. Successful completion of trials and consequent approval is expected to drive market growth over the forecast period. In February 2021, the US FDA granted breakthrough therapy designation to Tipifarnib developed by Kura Oncology, Inc., for the treatment of patients with head and neck squamous cell carcinoma (HNSCC). This is a potent, selective, and orally administered drug which will aid in market expansion.
The increasing prevalence of PD1 Resistant Head and Neck Cancer due to several factors such as alcohol consumption, tobacco consumption, Epstein-Barr virus (EBV) infection, and human papillomavirus (HPV) infection is significantly propelling the demand for PD1 Resistant Head and Neck Cancer drugs that bolsters HNC therapeutics market.
Report Attribute | Details |
---|---|
Expected Market Value (2023) | US$ 1.54 Billion |
Anticipated Forecast Value (2033) | US$ 5 Billion |
Projected Growth Rate (2023 to 2033) | CAGR 12.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The PD1 Resistant Head and Neck Cancer Market were growing at a CAGR of 10.1% while valued at US$ 1 Billion during the historical period. The rapidly growing pharmaceutical industry and the rising expenditure by the top market players in research and development and the availability of various pipeline drugs such as atezolizumab, Afatinib, and Ipilimumab are fuelling the market growth. Considering these factors HNC market is projected to reach US$ 5 Billion with a CAGR of 12.5% during the forecast period.
Advances in biochemistry and Genomics to propel market growth
The advancements in non-surgical procedures and therapies such as immunotherapy and targeted therapy are supporting the adoption rate of PD1-resistant head and neck cancer drugs among patients across the globe. The availability of advanced diagnostic tools to diagnose various types of cancer and tumors is driving market growth.
The increasing awareness among the population regarding the availability of effective and innovative drugs to treat cancer coupled with rising healthcare expenditure is fuelling the PD1-resistant head and neck cancer market growth. The swiftly growing biopharmaceutical industry and the rising penetration of online pharmacies are the major factors that are anticipated to augment the growth of the market during the forecast period.
Moreover, several developmental strategies such as partnerships, new product launches, and adoption of the latest technologies impact the market positively and drive the industry’s growth. The growing expenditure by the top market players in research and development and the availability of various pipeline drugs such as atezolizumab, Afatinib, and Ipilimumab is also aiding in market expansion.
High rate of complications to restrain market expansion
Rising treatment costs, an increase in the adverse effects associated with the use of PD1 Resistant Head and Neck Cancerdrugs, high rate of complications, dearth of early cancer detection, and lack of awareness among patients and physicians about head and neck treatment are the major factors acting as restraints, and will further hinder the PD1 Resistant Head and Neck Cancerdrug market during the forecast period. Moreover, the dearth of proper healthcare facilities and oncology professionals across some developing and underdeveloped regions is also restricting market expansion.
North American PD1-resistant head and neck cancer market accounted for 46% market share in 2022. It is estimated to retain its dominance while exhibiting a CAGR of 11.1% during the forecast period. In this region, the US market is expected to gross a market value of US$ 850 Million by end of the forecast period.
The presence of advanced healthcare infrastructure, robust product pipeline increased healthcare expenditure, favorable reimbursement policies, and improved access to advanced diagnostic devices are the major factors that drive the growth of the PD1 Resistant Head and Neck Cancer drugs market in the North American region.
In Asia Pacific, the market is projected to grow with the fastest CAGR of 11.5% with a market valuation to reach US$ 425 Million by 2033. The growing geriatric population and increasing prescription of immunotherapy drugs such as Pembrolizumab (Keytruda) and Nivolumab (Opdivo) for the treatment of various types of HNC are anticipated to drive market growth in coming years. China is expected to dominate the market in this region with a market valuation of around US$ 250 Million. Moreover, the market in Japan will be fuelled with a CAGR of 11%. Additionally, the Indian market will witness a CAGR of 11.2% during the forecast period.
Currently, four targeted therapies are existing in the APAC HNC market, which are Erbitux, BIOMAb EGFR, Opdivo, and Keytruda. The remainder of this market is composed of generics. Recent additions to the market have highlighted that the treatment landscape is diversifying and becoming less dependent on chemotherapy options.
With the approval of Keytruda in Australia, and Opdivo in Australia, South Korea, and Japan, there has been a rise in targeted therapy options. Additionally, avelumab (a PD-L1 inhibitor) is likely to be approved in APAC countries at the end of 2033, as it is currently undergoing Phase III trials in Japan, Australia, and South Korea.
Increasing demand for efficient drugs for the treatment of HNCs in emerging economies such as China and India, the growing pharmaceutical industry, and the rapidly increasing patient population are expected to fuel the growth of the market in Asia Pacific during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The increasing special drug designations and the high efficacy of EGFR inhibitors in the treatment of cancer indications e.g., lung cancer, colorectal cancer, and breast cancer will result in quicker approval during the clinical stages.
Thus, the robust prevalence of major cancer indications will be a significant factor driving the epidermal growth factor receptor inhibitors market during the forecast period.
The PD-1 inhibitors segment is projected to dominate the market owing to the increased volume of research activities, approvals, and increase in prescriptions of these drugs such as nivolumab and pembrolizumab. Furthermore, the rising adoption of pembrolizumab (KEYTRUDA), due to its proven efficiency to treat multiple FDA-Approved indications like melanoma, non–small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), has also positively influenced the segment growth.
Additionally, the PD-L1 inhibitor segment is anticipated to witness the fastest CAGR during the forecast period owing to a sharp rise in the adoption of durvalumab (IMFINZI), avelumab (BAVENCIO), and others in the segment. Huge investments by the key players in the development of these products are further anticipated to fuel the segment growth over the forecast period.
Key players in the PD1 Resistant Head and Neck Cancer Market are Advaxis, Inc, Amgen, Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cel-Sci Corporation, GlaxoSmithKline plc, Incyte Corporation, Merck KGaA, Novartis AG.
Some Recent Developments in this industry are:
Report Attribute | Details |
---|---|
Market Value in 2023 | US$ 1.54 Billion |
Market Value in 2033 | US$ 5 Billion |
Growth Rate | CAGR of 12.5% from 2023 to 2033 |
Base Year for Estimation | 2022 |
Historical Data | 2018 to 2022 |
Forecast Period | 2023 to 2033 |
Quantitative Units | Revenue in US$ Billion and million and CAGR from 2023 to 2033 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization | Available Upon Request |
FMI projects the global PD1 Resistant Head and Neck Cancer Market to expand at a 12.5% value CAGR by 2033.
The global PD1 Resistant Head and Neck Cancer Market are expected to garner a market value of US$ 5 billion by 2033.
FMI has projected North America to be one of the most profitable regions for the PD1 Resistant Head and Neck Cancer Market.
APAC region is expected to grow fastest during the forecast period.
1. Executive Summary | PD1 Resistant Head and Neck Cancer Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Investment Feasibility Matrix
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Product, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product, 2023 to 2033
5.3.1. Cytotoxic Agents
5.3.1.1. Antimetabolites
5.3.1.2. Antitubulins
5.3.1.3. Others - Platinum Agents, Fluoropyrimidines
5.3.2. EGFR Inhibitors
5.3.2.1. Erbitux
5.3.2.2. Vectibix
5.3.2.3. Theracim/Theraloc
5.3.3. EGFR Inhibitors
5.3.3.1. Tarceva
5.3.3.2. Tykerb/Tyverb
5.3.4. PD1 Inhibitors
5.3.4.1. Keytruda
5.3.4.2. Opdivo
5.3.5. Pipeline Drugs
5.3.5.1. EGFR Inhibitors
5.3.5.2. PDL1 Inhibitors
5.3.5.3. CTLA4 Inhibitors
5.4. Y-o-Y Growth Trend Analysis By Product, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
6.1. Introduction
6.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
6.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Market Attractiveness Analysis By Region
7. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
7.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
7.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
7.2.1. By Country
7.2.1.1. The US
7.2.1.2. Canada
7.2.2. By Product
7.3. Market Attractiveness Analysis
7.3.1. By Country
7.3.2. By Product
7.4. Key Takeaways
8. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. Brazil
8.2.1.2. Mexico
8.2.1.3. Rest of Latin America
8.2.2. By Product
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Product
8.4. Key Takeaways
9. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Germany
9.2.1.2. The UK
9.2.1.3. France
9.2.1.4. Spain
9.2.1.5. Italy
9.2.1.6. Russia
9.2.1.7. Rest of Europe
9.2.2. By Product
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product
9.4. Key Takeaways
10. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. China
10.2.1.2. Japan
10.2.1.3. India
10.2.1.4. South Korea
10.2.1.5. Australia
10.2.1.6. Rest of APAC
10.2.2. By Product
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product
10.4. Key Takeaways
11. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. South Africa
11.2.1.2. Saudi Arabia
11.2.1.3. UAE
11.2.1.4. Israel
11.2.1.5. Rest of MEA
11.2.2. By Product
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product
11.4. Key Takeaways
12. Key Countries Market Analysis
12.1. The US
12.1.1. Pricing Analysis
12.1.2. Market Share Analysis, 2022
12.1.2.1. By Product
12.2. Canada
12.2.1. Pricing Analysis
12.2.2. Market Share Analysis, 2022
12.2.2.1. By Product
12.3. Brazil
12.3.1. Pricing Analysis
12.3.2. Market Share Analysis, 2022
12.3.2.1. By Product
12.4. Mexico
12.4.1. Pricing Analysis
12.4.2. Market Share Analysis, 2022
12.4.2.1. By Product
12.5. Germany
12.5.1. Pricing Analysis
12.5.2. Market Share Analysis, 2022
12.5.2.1. By Product
12.6. The UK
12.6.1. Pricing Analysis
12.6.2. Market Share Analysis, 2022
12.6.2.1. By Product
12.7. France
12.7.1. Pricing Analysis
12.7.2. Market Share Analysis, 2022
12.7.2.1. By Product
12.8. Spain
12.8.1. Pricing Analysis
12.8.2. Market Share Analysis, 2022
12.8.2.1. By Product
12.9. Italy
12.9.1. Pricing Analysis
12.9.2. Market Share Analysis, 2022
12.9.2.1. By Product
12.10. Russia
12.10.1. Pricing Analysis
12.10.2. Market Share Analysis, 2022
12.10.2.1. By Product
12.11. China
12.11.1. Pricing Analysis
12.11.2. Market Share Analysis, 2022
12.11.2.1. By Product
12.12. Japan
12.12.1. Pricing Analysis
12.12.2. Market Share Analysis, 2022
12.12.2.1. By Product
12.13. India
12.13.1. Pricing Analysis
12.13.2. Market Share Analysis, 2022
12.13.2.1. By Product
12.14. South Korea
12.14.1. Pricing Analysis
12.14.2. Market Share Analysis, 2022
12.14.2.1. By Product
12.15. Australia
12.15.1. Pricing Analysis
12.15.2. Market Share Analysis, 2022
12.15.2.1. By Product
12.16. South Africa
12.16.1. Pricing Analysis
12.16.2. Market Share Analysis, 2022
12.16.2.1. By Product
12.17. Saudi Arabia
12.17.1. Pricing Analysis
12.17.2. Market Share Analysis, 2022
12.17.2.1. By Product
12.18. UAE
12.18.1. Pricing Analysis
12.18.2. Market Share Analysis, 2022
12.18.2.1. By Product
12.19. Israel
12.19.1. Pricing Analysis
12.19.2. Market Share Analysis, 2022
12.19.2.1. By Product
13. Market Structure Analysis
13.1. Competition Dashboard
13.2. Competition Benchmarking
13.3. Market Share Analysis of Top Players
13.3.1. By Regional
13.3.2. By Product
14. Competition Analysis
14.1. Competition Deep Dive
14.1.1. Advaxis, Inc.
14.1.1.1. Overview
14.1.1.2. Product Portfolio
14.1.1.3. Profitability by Market Segments
14.1.1.4. Sales Footprint
14.1.1.5. Strategy Overview
14.1.1.5.1. Marketing Strategy
14.1.2. Amgen, Inc.
14.1.2.1. Overview
14.1.2.2. Product Portfolio
14.1.2.3. Profitability by Market Segments
14.1.2.4. Sales Footprint
14.1.2.5. Strategy Overview
14.1.2.5.1. Marketing Strategy
14.1.3. AstraZeneca plc
14.1.3.1. Overview
14.1.3.2. Product Portfolio
14.1.3.3. Profitability by Market Segments
14.1.3.4. Sales Footprint
14.1.3.5. Strategy Overview
14.1.3.5.1. Marketing Strategy
14.1.4. Boehringer Ingelheim GmbH
14.1.4.1. Overview
14.1.4.2. Product Portfolio
14.1.4.3. Profitability by Market Segments
14.1.4.4. Sales Footprint
14.1.4.5. Strategy Overview
14.1.4.5.1. Marketing Strategy
14.1.5. Bristol-Myers Squibb Company
14.1.5.1. Overview
14.1.5.2. Product Portfolio
14.1.5.3. Profitability by Market Segments
14.1.5.4. Sales Footprint
14.1.5.5. Strategy Overview
14.1.5.5.1. Marketing Strategy
14.1.6. Cel-Sci Corporation
14.1.6.1. Overview
14.1.6.2. Product Portfolio
14.1.6.3. Profitability by Market Segments
14.1.6.4. Sales Footprint
14.1.6.5. Strategy Overview
14.1.6.5.1. Marketing Strategy
14.1.7. GlaxoSmithKline plc
14.1.7.1. Overview
14.1.7.2. Product Portfolio
14.1.7.3. Profitability by Market Segments
14.1.7.4. Sales Footprint
14.1.7.5. Strategy Overview
14.1.7.5.1. Marketing Strategy
14.1.8. Incyte Corporation
14.1.8.1. Overview
14.1.8.2. Product Portfolio
14.1.8.3. Profitability by Market Segments
14.1.8.4. Sales Footprint
14.1.8.5. Strategy Overview
14.1.8.5.1. Marketing Strategy
14.1.9. Merck KGaA
14.1.9.1. Overview
14.1.9.2. Product Portfolio
14.1.9.3. Profitability by Market Segments
14.1.9.4. Sales Footprint
14.1.9.5. Strategy Overview
14.1.9.5.1. Marketing Strategy
14.1.10. Novartis AG
14.1.10.1. Overview
14.1.10.2. Product Portfolio
14.1.10.3. Profitability by Market Segments
14.1.10.4. Sales Footprint
14.1.10.5. Strategy Overview
14.1.10.5.1. Marketing Strategy
15. Assumptions & Acronyms Used
16. Research Methodology
Explore Healthcare Insights
View Reports